Clinical Trials on TNBC, Triple Negative Breast Cancer in Japan
Total 203 results
-
Novartis PharmaceuticalsTerminatedTriple Negative Breast Cancer (TNBC)Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Okayama UniversityMerck Sharp & Dohme LLCRecruitingBreast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast CarcinomaJapan
-
Novartis PharmaceuticalsCompletedTriple-negative Breast CancerBelgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Hoffmann-La RocheCompletedTriple-negative Breast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Belgium, Brazil, Germany, Taiwan, Australia, Japan, Spain, Poland, Italy
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerFrance, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerIsrael, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
AstraZenecaSWOG Clinical Trials Partnerships; Daiichi SankyoRecruitingBreast CancerUnited States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
-
Hoffmann-La RocheCompletedBreast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, Brazil, France, Slovenia, Spain, Taiwan, Japan, Italy, Argentina, India, Germany, Hungary, Russian Federation, Singapore, Ukraine, Costa Rica, Czechia, G... and more
-
Hoffmann-La RocheCompletedTriple Negative Breast CancerUnited States, Korea, Republic of, Belgium, Canada, Germany, United Kingdom, Argentina, Australia, Brazil, Finland, France, Greece, Hungary, Poland, Slovenia, Spain, Taiwan, Turkey, Japan, Singapore, Colombia, Bosnia and Herzegovina, Guatema... and more
-
Hoffmann-La RocheBreast International Group; Frontier Science & Technology Research Foundation... and other collaboratorsCompletedTriple Negative Breast CancerRussian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
-
Novartis PharmaceuticalsTerminatedOvarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
GlaxoSmithKlineActive, not recruitingNeoplasms, BreastUnited States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, France, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Turkey, Brazil, Japan, Taiwan, Thailand, Canada, Singapore, Mexico, Argentina, Germany, India, Philippines, Poland, South Africa
-
Novartis PharmaceuticalsCompletedEsophageal Cancer | Triple Negative Breast Cancer | Head & Neck CancerFrance, Singapore, Italy, Japan, United States, Spain
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
Eli Lilly and CompanyTerminatedHepatocellular Carcinoma | Solid Tumor | Gastric Adenocarcinoma | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Cervical Carcinoma | Triple-negative Breast Cancer | Undifferentiated Pleomorphic Sarcoma | High Grade Serous Ovarian CarcinomaUnited States, Japan
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
-
Novartis PharmaceuticalsActive, not recruitingAdvanced Solid Tumors | Triple Negative Breast Cancer | Chordoma and Alveolar Soft Part SarcomaUnited States, Taiwan, Spain, Canada, Singapore, Italy, Japan, Israel, France
-
Osaka Medical CollegeTerminatedBreast Cancer | HER-2 Positive Breast Cancer | Estrogen Receptor Negative NeoplasmJapan
-
Merck Sharp & Dohme LLCActive, not recruitingTriple Negative Breast NeoplasmsBrazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
-
AstraZenecaActive, not recruitingTriple Negative Breast NeoplasmsUnited States, Spain, Sweden, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Hungary, India, Japan, Mexico, Peru, Philippines, Poland, China, Malaysia, Canada, Portugal and more
-
Eisai Co., Ltd.CompletedBreast Cancer | HER2-negative Breast CancerJapan
-
AbbVieRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell CarcinomaUnited States, Israel, Japan, Puerto Rico
-
Merck Sharp & Dohme LLCActive, not recruitingTriple Negative Breast NeoplasmsColombia, United States, Canada, Chile, France, Germany, Hungary, Ireland, Japan, Korea, Republic of, Poland, Spain, Taiwan, Ukraine, United Kingdom
-
Novartis PharmaceuticalsCompletedMelanoma | Triple Negative Breast Cancer | Endometrial Carcinoma | Pancreatic CarcinomaUnited States, Germany, Italy, Japan, Belgium, Switzerland, Korea, Republic of, Hong Kong, Finland, France, Spain
-
National Cancer Center, JapanRecruitingCervical Cancer | Nasopharyngeal Carcinoma | Ovarian Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Clear Cell CarcinomaJapan, Korea, Republic of, Malaysia, Thailand, Philippines, Singapore, Taiwan, Vietnam
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
Novartis PharmaceuticalsActive, not recruitingMelanoma | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Triple Negative Breast Cancer | Microsatellite Stable Colorectal CancerUnited States, Taiwan, Spain, Germany, Japan, Hong Kong
-
TakedaCompletedPremenopausal Breast CancerJapan
-
Tokyo Medical UniversityTokyo University; Saint Luca International HospitalCompleted
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
Osaka Medical CollegeCompletedBreast Cancer | Effects of Chemotherapy | HER-2 Positive Breast CancerJapan
-
AstraZenecaCompletedNeoplasms | Breast Cancer | Metastatic CancerJapan
-
Nippon Kayaku Co., Ltd.CompletedBreast Cancer Nos Metastatic RecurrentJapan
-
Eli Lilly and CompanyCompletedBreast Cancer | Metastatic Breast CancerJapan
-
Tokyo Medical and Dental UniversityRecruitingBreast Cancer | Metastatic Breast Cancer | OligometastasisJapan
-
National Cancer Center, JapanH.U. Group Research Institute G.K.RecruitingHER2-positive Breast CancerJapan
-
Chugai PharmaceuticalCompleted
-
Japanese Foundation for Cancer ResearchChugai PharmaceuticalActive, not recruiting
-
Kyoto Breast Cancer Research NetworkCompleted
-
AgendiaOsaka General Medical CenterCompleted
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerJapan
-
National Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerUnited States, Japan